Amphastar Pharmaceuticals (AMPH) Revenue & Revenue Breakdown
Amphastar Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$593.24M
Latest Revenue (Q)
$188.82M
Main Segment (Y)
Active Pharmaceutical Ingredient Segment
Main Geography (Y)
U
Amphastar Pharmaceuticals Revenue by Period
Amphastar Pharmaceuticals Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $593.24M | 18.89% |
2022-12-31 | $498.99M | 13.98% |
2021-12-31 | $437.77M | 25.13% |
2020-12-31 | $349.85M | 8.53% |
2019-12-31 | $322.36M | 9.40% |
2018-12-31 | $294.67M | 22.69% |
2017-12-31 | $240.18M | -5.87% |
2016-12-31 | $255.16M | 1.45% |
2015-12-31 | $251.52M | 19.51% |
2014-12-31 | $210.46M | -8.37% |
2013-12-31 | $229.68M | 12.41% |
2012-12-31 | $204.32M | 72.63% |
2011-12-31 | $118.36M | - |
Amphastar Pharmaceuticals Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | $188.82M | 3.52% |
2024-06-30 | $182.39M | 6.14% |
2024-03-31 | $171.84M | -3.52% |
2023-12-31 | $178.10M | -1.36% |
2023-09-30 | $180.56M | 23.91% |
2023-06-30 | $145.71M | 4.06% |
2023-03-31 | $140.02M | 3.70% |
2022-12-31 | $135.02M | 12.40% |
2022-09-30 | $120.13M | -2.70% |
2022-06-30 | $123.47M | 2.57% |
2022-03-31 | $120.37M | -0.43% |
2021-12-31 | $120.89M | 7.74% |
2021-09-30 | $112.20M | 10.36% |
2021-06-30 | $101.66M | -1.32% |
2021-03-31 | $103.02M | 7.40% |
2020-12-31 | $95.92M | 14.97% |
2020-09-30 | $83.43M | -2.77% |
2020-06-30 | $85.81M | 1.32% |
2020-03-31 | $84.69M | 1.57% |
2019-12-31 | $83.38M | 4.05% |
2019-09-30 | $80.14M | 1.38% |
2019-06-30 | $79.05M | -0.93% |
2019-03-31 | $79.79M | -11.04% |
2018-12-31 | $89.69M | 18.73% |
2018-09-30 | $75.54M | 6.34% |
2018-06-30 | $71.04M | 21.66% |
2018-03-31 | $58.39M | -3.33% |
2017-12-31 | $60.40M | 4.29% |
2017-09-30 | $57.92M | -11.15% |
2017-06-30 | $65.19M | 15.03% |
2017-03-31 | $56.67M | -10.82% |
2016-12-31 | $63.54M | -1.06% |
2016-09-30 | $64.22M | -5.60% |
2016-06-30 | $68.03M | 14.60% |
2016-03-31 | $59.37M | -22.81% |
2015-12-31 | $76.91M | 20.42% |
2015-09-30 | $63.87M | 18.60% |
2015-06-30 | $53.85M | -5.33% |
2015-03-31 | $56.89M | 1.81% |
2014-12-31 | $55.88M | -6.42% |
2014-09-30 | $59.71M | 21.85% |
2014-06-30 | $49.00M | 6.83% |
2014-03-31 | $45.87M | -16.41% |
2013-12-31 | $54.88M | -7.49% |
2013-09-30 | $59.32M | -5.13% |
2013-06-30 | $62.52M | 18.05% |
2013-03-31 | $52.96M | - |
Amphastar Pharmaceuticals Revenue Breakdown
Amphastar Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 20 | Dec 19 | Dec 18 |
---|---|---|---|
Active Pharmaceutical Ingredient Segment | $18.48M | $20.36M | $23.61M |
Latest
Quarterly Revenue by Product
Product/Service | Sep 24 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Product and Service, Other | $2.40M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Product | $188.82M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Active Pharmaceutical Ingredient Segment | - | $6.94M | $5.14M | $8.12M | $2.10M | $4.87M | $3.39M | $5.39M | $4.41M | $5.31M | $5.25M | $3.78M | $7.80M | $5.28M | - |
Finished Pharmaceutical Products Segment | - | - | - | - | - | - | - | - | - | - | - | $82.93M | - | - | - |
Latest
Amphastar Pharmaceuticals Revenue Breakdown by Country
Annual Revenue by Country
Country | Dec 20 | Dec 19 | Dec 18 |
---|---|---|---|
Active Pharmaceutical Ingredient Segment | $18.48M | - | - |
C | $3.16M | $1.48M | - |
U | $333.09M | $304.90M | $279.12M |
Latest
Quarterly Revenue by Country
Country | Sep 24 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | Mar 18 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CHINA | $178.00K | - | - | - | - | - | - | - | - | - | - | - | - | - |
FRANCE | $4.52M | - | - | - | - | - | - | - | - | - | - | - | - | - |
UNITED STATES | $186.51M | - | - | - | - | - | - | - | - | - | - | - | - | - |
C | - | $1.13M | $1.12M | $679.00K | $1.96M | $295.00K | $228.00K | $438.00K | $59.00K | $984.00K | - | - | - | - |
U | - | $95.19M | $99.17M | $90.72M | $79.41M | $81.90M | $81.06M | $77.59M | $76.07M | $74.78M | $76.46M | $72.48M | $68.56M | $53.10M |
Active Pharmaceutical Ingredient Segment | - | $6.94M | - | - | - | - | - | - | - | - | - | - | - | - |
Latest
Amphastar Pharmaceuticals Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
NBIX | Neurocrine Biosciences | $1.89B | $622.10M |
ALKS | Alkermes | $1.66B | $378.14M |
PBH | Prestige Consumer Healthcare | $1.13B | $283.55M |
PAHC | Phibro Animal Health | $977.89M | $273.16M |
EVO | Evotec SE | $781.43M | $208.73M |
PCRX | Pacira BioSciences | $674.98M | $168.57M |
SUPN | Supernus Pharmaceuticals | $607.52M | $175.69M |
AMPH | Amphastar Pharmaceuticals | $593.24M | $188.82M |
COLL | Collegium Pharmaceutical | $566.77M | $159.30M |
ANIP | ANI Pharmaceuticals | $486.82M | $148.33M |
IRWD | Ironwood Pharmaceuticals | $442.74M | $91.59M |
EGRX | Eagle Pharmaceuticals | $316.61M | $64.65M |
EOLS | Evolus | $199.72M | $60.16M |
DCPH | Deciphera Pharmaceuticals | $163.36M | $45.00M |